Markets
CBM

Increased Earnings Estimates Seen for Cambrex Corporation (CBM): Can It Move Higher? - Tale of the Tape

Cambrex Corporation ( CBM ) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CBM's earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Cambrex Corporation could be a solid choice for investors.

Current Quarter Estimates for CBM

In the past 30 days, 1 estimate has gone higher for Cambrex Corporation while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 19 cents a share 30 days ago, to 24 cents today, a move of 26.3%.

Current Year Estimates for CBM

Meanwhile, Cambrex Corporation's current year consensus estimate trend is also looking quite promising, with estimates increasing from $1.20 per share 30 days ago to $1.69 per share today, an increase of 40.8%.

Bottom Line

The stock has also started to move higher lately, adding 47.4% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #1 (Strong Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

CAMBREX CORP (CBM): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CBM

Other Topics

Earnings Investing Stocks